Patents Represented by Attorney Law Office of John K. Pike, PLLC
-
Patent number: 8034840Abstract: The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their use.Type: GrantFiled: June 22, 2007Date of Patent: October 11, 2011Assignee: Cytokine PharmaSciences, Inc.Inventor: Thais M. Seilecki-Dzurdz
-
Patent number: 7927760Abstract: A direct methanol fuel cell unit is provided with a fuel cell including an anode, a cathode with a hydrophobic microporous layer, an electrolyte membrane put in-between, and a fuel supply path supplying fuel to the anode. The fuel supply path is provided with an upwind water barrier preventing back-diffusion of water and a gas flow path channeling gas generated at the anode and disposed between the barrier and the anode. A water-rich zone is formed between the water barrier and the cathode microporous layer. Water loss from either side of this zone is eliminated or minimized, thereby permitting direct use of highly concentrated methanol in the fuel flow path with good fuel efficiency and power performance. The cell unit can be applied equally well to both an active circulating air cathode and an air-breathing cathode.Type: GrantFiled: December 17, 2004Date of Patent: April 19, 2011Assignees: The Penn State Research Foundation, Kabushiki Kaisha ToshibaInventors: Chao-Yang Wang, Guoqiang Lu, Wenpeng Liu, Fuqiang Liu, Yuusuke Sato, Eiichi Sakaue, Kei Matsuoka
-
Patent number: 7928130Abstract: Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatoid arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).Type: GrantFiled: January 27, 2009Date of Patent: April 19, 2011Assignee: Cytokine PharmaSciences, Inc.Inventor: Yousef Al-Abed
-
Patent number: 7863334Abstract: The present invention relates to compounds having the formula: salts thereof; compositions comprising one or more of the compounds and/or salts thereof; methods of using; and methods of making.Type: GrantFiled: September 17, 2007Date of Patent: January 4, 2011Assignee: Cytokine PharmaSciences, Inc.Inventor: Thais M. Sielecki-Dzurdz
-
Patent number: 7815384Abstract: A device for applying a coating comprises at least two cylindrical cartridges, a static mixing nozzle in fluid communication with the cartridges, a spray tip, in fluid communication with the nozzle, a first flexible hose disposed between and in fluid communication with the nozzle and the spray tip, and a second hose, in fluid communication with the spray tip, for supplying atomization air to the spray tip. Methods of applying coatings with the device are also provided.Type: GrantFiled: November 28, 2006Date of Patent: October 19, 2010Assignee: Richard Parks Corrosion Technologies, Inc.Inventors: Richard Parks, Heather Parks
-
Patent number: 7795314Abstract: A method is described wherein semapimod is administered, or a salt thereof, or a combination of semapimod and a salt thereof, for the treatment of necrotizing enterocolitis.Type: GrantFiled: June 1, 2006Date of Patent: September 14, 2010Assignee: Cytokine PharmaSciences, Inc.Inventors: Ruben Zamora, Henri R. Ford, Thais Sielecki-Dzurdz, Vidal F. De La Cruz
-
Patent number: 7741372Abstract: There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.Type: GrantFiled: July 16, 2003Date of Patent: June 22, 2010Assignee: Cytokine PharmaSciences, Inc.Inventors: Kevin J. Tracey, Pamela Cohen, Michael Bukrinsky, Helena Schmidtmayerova
-
Patent number: 7741057Abstract: Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.Type: GrantFiled: October 31, 2007Date of Patent: June 22, 2010Assignee: Cytokine PharmaSciences, Inc.Inventors: Richard J. Bucala, Lin Leng, Christine N. Metz
-
Patent number: 7662843Abstract: Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatiod arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).Type: GrantFiled: April 21, 2004Date of Patent: February 16, 2010Assignee: Cytokine PharmaSciences, Inc.Inventor: Yousef Al-Abed
-
Patent number: 7517523Abstract: The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the uses of such compositions and methods for the treatment of various conditions involving cytokine-mediated toxicity, which include, but are not limited to shock, inflammation, graft versus host disease, and/or autoimmune diseases.Type: GrantFiled: June 17, 2003Date of Patent: April 14, 2009Assignee: Cytokine PharmaSciences, Inc.Inventors: Richard Bucala, Robert A. Mitchell, Jurgen Bernhagen, Thierry F. Calandra, Anthony Cerami
-
Patent number: 7491740Abstract: Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatiod arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).Type: GrantFiled: June 10, 2002Date of Patent: February 17, 2009Assignee: Cytokine PharmaSciences, Inc.Inventor: Yousef Al-Abed
-
Patent number: 7244765Abstract: The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their use.Type: GrantFiled: June 24, 2005Date of Patent: July 17, 2007Assignee: Cytokine Pharmasciences, IncInventor: Thais M. Sielecki-Dzurdz